Data Sheet 1_Comparative effectiveness and safety of biologics and targeted small-molecule

32 randomized controlled trials involving 17,121 patients form the basis of this systematic review and network meta-analysis. Wenjuan Li published the findings in May 2026, comparing the efficacy and safety of biologics and targeted small-molecule drugs for systemic lupus erythematosus. The analysis includes multiple clinical endpoints such as SRI-4, BICLA, CLASI-50, and LLDAS response rates.

Use Cases

• Compare the relative efficacy of different biologics and targeted small-molecule drugs based on SRI-4 response rates.
• Assess the safety profiles of SLE treatments based on adverse event, serious adverse event, and infection-related adverse event rates.
• Identify promising therapies for SLE with cutaneous manifestations based on CLASI-50 improvement data.
• Inform clinical trial design by benchmarking new interventions against established treatments using network meta-analysis results.

Strengths

• Analysis is based on 32 randomized controlled trials, a substantial evidence base.
• The dataset includes results for 17,121 patients, providing statistical power.
• The study uses multiple standardized clinical endpoints (SRI-4, BICLA, CLASI-50, LLDAS) for comprehensive assessment.
• The work is a formal systematic review registered with PROSPERO (CRD42024594766).

Limitations

• The underlying data is presented as a PDF summary report; raw, row-level trial data is not provided.
• Column-level documentation for any potential supplementary data is absent; field semantics must be inferred from the report.
• The 6.4 MB file size suggests a small, summarized dataset rather than a large, granular data repository.

Provenance

Source

figshare

Collection Method

Systematic review and network meta-analysis of randomized controlled trials sourced from PubMed, EMBASE, and Cochrane Library.

Freshness

Last updated 2026-05-01 05:27:54.